Clinical trials: Relapse Schizophrenia
Schizophrenia
PREvent First Episode Relapse (PREFER)
Many patients who have recently received a diagnosis of schizophrenia (e.g., "first-episode schizophrenia") respond very well to their antipsychotic medication when they are acutely ill.
- Trial name
- NCT00220714
- Testing
- atypical antipsychotics:oral vs. long-acting route, Family Psychoeducation
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- State University of New York - Downstate Medical Center
Schizophrenia, Schizophrenia Relapse
Risk of Breakthrough Symptoms With Long-Acting Injectable Medications
This prospective longitudinal cohort study will follow patients with schizophrenia who are treated with second generation long-acting injectable antipsychotic medications (LAIs) for 48 weeks to determine the risk of psychotic…
- Trial name
- NCT05473741
- Testing
- Second Generation Long-Acting Injectable Antipsychotic Medications
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
- Trial name
- NCT01529515
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 53 sites in United States, Colombia and 6 more
- Volunteers
- 509 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Psychotic Disorders
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine…
- Trial name
- NCT00216476
- Testing
- Aripiprazole, Risperidone Long Acting Injectable (LAI), Quetiapine
- Where
- 96 sites in Austria, Bulgaria and 22 more
- Volunteers
- 753 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia
To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia is a brain disease. The condition may be associated with acute psychotic episodes and long-term disability despite remission from the acute symptoms.
- Trial name
- NCT00150176
- Testing
- Asenapine - Open Label, Asenapine - Double Blind
- Volunteers
- 831 people
- Sponsor
- Organon and Co
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizoaffective Disorder
Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Schizoaffective
The purpose of this study is to evaluate the efficacy of repetitive transcranial magnetic stimulation in the prevention of relapse of the symptoms of schizoaffective disorder.
- Trial name
- NCT02221635
- Testing
- rTMS + risperidone, Risperidone
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Xijing Hospital
Schizophrenia, Schizoaffective Disorder
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
The purpose of this study is to evaluate epidemiological characteristics of patients that experience relapse and need an admission in psychiatric acute units across Spain.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00399334
- Testing
- antipsychotic medications
- Volunteers
- 1,607 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia
Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia
The purpose of this study is to establish and validate a scale/model that can be used to evaluate the duration of time and factors between short term hospital treatment and subsequent relapse periods in patients with…
- Trial name
- PRE-COG (NCT00358852)
- Testing
- No intervention
- Volunteers
- 2,339 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Schizoaffective Disorder
Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
To evaluate the efficacy, safety and tolerability of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder with risperidone as an active control.
- Trial name
- NCT00283179
- Testing
- Aripiprazole, Risperidone
- Where
- Taiwan
- Volunteers
- 83 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Psychosis
A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine
The investigators are going to observe if add-on of n-acetylcysteine (NAC) 1200 or 2400 mg/d during tapering of antipsychotics in patients with remitted psychosis can help to reduce the pre-requisite of stabilization to 3 months…
- Trial name
- NCT06546475
- Testing
- N-Acetylcysteine
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Relapse Schizophrenia
A RCT Study in Schizophrenia Relapse Prevention
THE AIM OF THE PROJECT The main aim lies in the prevention of frequent relapses typical for schizophrenia and schizoaffective disorder by means of simple, highly cost-effective information technology-aided approach RESEARCH…
- Trial name
- NCT01885923
- Testing
- ITAREPS
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- Prague Psychiatric Center
Schizophrenia
Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of…
- Trial name
- NCT04959032
- Testing
- Lumateperone 42 mg
- Where
- 43 sites in United States, Bulgaria and 2 more
- Volunteers
- 592 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Schizoaffective Disorder
Smoking Relapse Prevention in Schizophrenia
This study seeks to determine if continued treatment with bupropion and nicotine replacement therapy (NRT) can reduce the smoking relapse rate in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Smokers
- Trial name
- NCT00320697
- Testing
- bupropion + nicotine patch + nicotine gum or lozenges
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizoaffective Disorder
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
This study will evaluate the efficacy of paliperidone palmitate compared with placebo in the delay of relapse of the symptoms of schizoaffective disorder.
- Trial name
- NCT01193153
- Testing
- paliperidone palmitate
- Where
- 80 sites in United States, Bulgaria and 6 more
- Volunteers
- 667 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia
Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
The goal of this project is to show that the best possible option for preventing relapses in patients suffering from first episode (<1 year of anti-psychotic medication) or early phase (< 5 years of lifetime exposure to…
- Trial name
- PRELAPSE (NCT02360319)
- Testing
- Any FDA approved antipsychotic agent, aripiprazole long acting injectable formulation
- Where
- 39 sites in United States
- Volunteers
- 489 people
- Sponsor
- Vanguard Research Group
Schizophrenia
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
This will be a multicenter, randomized, double-blind, placebo-controlled study designed to assess the tolerability, safety, and efficacy of OPC-34712 (0.25 to 6.0 mg) for the treatment of adult subjects hospitalized with an acute…
- Trial name
- STEP 203 (NCT00905307)
- Testing
- OPC-34712, Aripiprazole
- Where
- 73 sites in United States, Bulgaria and 10 more
- Volunteers
- 459 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Risperidone Maintenance Treatment in Schizophrenia
This study set out to determine the duration of maintenance treatment with therapeutic risperidone dose in schizophrenia. In a multi-center, open label, randomized, controlled study design, patients with schizophrenia who were…
- Trial name
- NCT00848432
- Testing
- risperidone
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Capital Medical University
Psychotic Disorder
Speech-based Assessment of Relapse Risk in People With Psychosis
This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis.
- Trial name
- TRUSTING-WP4 (NCT07397975)
- Testing
- Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.
- Where
- 7 sites in Czechia, Ireland and 4 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Philipp Homan
Schizophrenia
A Study for Schizophrenia Relapse Prediction
The purpose of this study is to identify if there are self-reported/caregiver reported or objective measures that can predict near-term relapse (within 1 month or at another identified time point before meeting the criteria for…
- Trial name
- NCT03629951
- Testing
- Oral Antipsychotics (OAP)
- Where
- 10 sites in India
- Volunteers
- 333 people
- Sponsor
- Janssen Research & Development, LLC